Vyome (HIND) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Vyome (HIND) over the past year, losing 46.2% versus a loss of 65.4%. Over five years, KTTA leads with a -99.3% price change compared with -100.0% for HIND. Pasithea Therapeutics is the larger company by market cap ($15.3 million vs $14.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | KTTA |
|---|---|---|
| Share price | $2.06 | $0.4568 |
| Market cap | $14.46M | $15.26M |
| 1-day change | +1.46% | +3.61% |
| YTD return | -40.99% | -65.82% |
| 1-year return | -65.42% | -46.23% |
| 5-year return | -100.00% | -99.26% |
| P/E ratio (TTM) | 1.16 | — |
| EPS (TTM) | $1.78 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.56 | $2.06 |
| 52-week low | $1.75 | $0.281 |
| Distance from 52-week high | -68.60% | -77.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +328.64% | +556.74% |
| Average volume | 13.32K | 225.69K |
| Shares outstanding | 7.02M | 33.41M |
| Employees | 9 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed HIND by 19.2 percentage points over the past year.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
HIND vs KTTA FAQ
Which is bigger, Vyome or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.26M compared with $14.46M for Vyome (HIND).
Which stock has performed better over the past year, HIND or KTTA?
KTTA returned -46.23% over the past 12 months, compared with -65.42% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.